PFIZER'S VARENICLINE RECEIVES FDA PRIORITY REVIEW

The FDA has granted a six-month priority review to Pfizer's new drug application for varenicline tartrate, an investigational smoking-cessation treatment that the company plans to market under the brand name Champix. The compound is intended to activate the brain receptor that is stimulated by nicotine, thereby easing withdrawal symptoms.